Sickle Cell Disease Clinical Trial
Official title:
Hematopoietic Stem Cell Transplant for Sickle Cell Disease
Verified date | April 2024 |
Source | Case Comprehensive Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a study of patients with sickle cell disease. It aims to find out if people with sickle cell disease can be cured by changing their immune system before they have blood stem cell transplants. Doctors will give patients a new drug (fludarabine) to see if this drug changes patients immune system and reduces the patient's cells (host) from rejecting donor cells (graft) after the patient gets a Hematopoietic (blood) stem cell transplant.
Status | Completed |
Enrollment | 4 |
Est. completion date | February 17, 2023 |
Est. primary completion date | February 17, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Patients must have one of the following inherited hemoglobin gene disorders: - a. Hemoglobin SS - b. Hemoglobin SC - c. Hemoglobin S-Beta-zero-Thalassemia or - d. Hemoglobin S-Beta-plus Thalassemia with an episode of multi-organ failure within 5 years of eligibility Patients must meet one of the following risk criteria: - Low Risk (Red Light. Stop and consider therapy closely): Must have matched sibling donor grafts, failed conventional therapy as determined by the PI, and evidence for morbid disease (one of the following): - a. 2 or more painful episode/year (requiring Emergency Department or inpatient care) x 2 years or - b. 1 or more diagnoses of Acute Chest Syndrome within 5 years, or - c. 2-year mortality 5-10% or - d. Baseline LDH>600 IU or - e. History of sepsis, with or without a WBC>13.5, or - f. On chronic transfusions - Moderate Risk (Yellow Light. Reasonable to proceed, but with caution): May have alternate donor grafts (haploidentical or matched unrelated donor), if MSD is not available. Must have history of high-level vasculopathy, as defined by at least one of the criteria below: - a. Urine Albumin to Creatinine Ratio of >300mg/g or eGFR 50-90 ml/min x 2 evaluations within 3 months or - b. History of overt clinical stroke, or progressive cerebral vasculopathy radiographically or - c. 1 or more diagnoses of Acute Chest Syndrome, multi-organ failure, or sickle hepatopathy within 7 years, or - d. Excessively morbid disease manifest as VOCs at a rate of 2 or more per year x 2-years or uncontolled retinal disease attributed to SCD. These patients can be considered for moderate-risk alternate donor transplants. The palliative nature of the transplant will be explicit in the consent. - e. 2-year mortality >10-15% - i. Baseline WBC>13.5 and on chronic transfusions or baseline LDH>600 or age >35 years old, - ii. Baseline TRV =3 m/s, - iii. Chronic transfusion therapy and age >35 years old or male gender, - iv. Baseline LDH>600 and age >35 years old or history of sepsis - v. History of sepsis and age >35 years old or male gender. - f. History of multi-organ failure - High Risk (Green light, proceed if possible): All donor types are eligible. Must have high risk disease and a >15% risk of 2-year mortality as defined by at least one of the criteria below. - a. Baseline TRV =3 m/s and baseline WBC >13.5 or on chronic transfusions or history of sepsis or age >35 years old, - b. Baseline WBC>13.5 and chronic transfusions or baseline LDH>600 or age >35 years old - c. Age >35 years old and chronic transfusions To determine eligibility as a bone marrow transplant patient: - Available suitable donor - a. 6/6 HLA-matched sibling donor (HLA A, B, and DRB1), bone marrow only - b. 8/8 HLA-matched unrelated donor (HLA A, B, C, DRB1), bone marrow only - c. 4/8, 5/8, 6/8, 7/8 Haploidentical donor, bone marrow only - Patients must have adequate hematologic, hepatic, and renal function as defined below: - Direct bilirubin within 3 X normal institutional limits - ALT (SGPT) < 3 X institutional upper limit of normal - Creatinine clearance >21 mL/min/1.73 m^2 for subjects with creatinine clearance values below 50 mL/min/1.73 m^2, the principal investigator may use discretion for appropriate fludarabine dose adjustment as noted. - Patients must have adequate pulmonary function as defined by Pulmonary function: DLCO r40% (adjusted for hemoglobin) and FEV1r50%. - Contraception/Child Bearing The effects of Fludarabine, cytoxan, ATG, tacrolimus/sirolimus and MTX are cumulatively known to be deleterious to the health of the developing human fetus. For this reason, and because of teratogenic potential, all women of child-bearing potential and men must agree to use adequate contraception (double barrier method of birth control or abstinence) for the duration of study participation and for 12 months after completing treatment. - Performance Status: Eastern Cooperative Oncology Group (ECOG) Performance Status = 2 - Subjects must have the ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: - Red cell alloimmunization to a degree that precludes extended transfusion - Patients with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements - Subjects must not have evidence of impaired liver function due to iron overload, +/- hepatitis. Patients will be evaluated by liver consult if ferritin >1500, history of hepatitis,or ALTis =3 X Upper limit of normal (ULN). Recommended evaluations could include liver biopsy if there is evidence for significant hepatic iron deposition or fibrosis/cirrhosis on T2* MRI of the liver. - eGFR <21 ml/min - =2.0 liter-per-minute pm home oxygen requirement - An estimated Left Ventricular Ejection Fraction =40% (echo or MUGA) - Hepatic cirrhosis (Biopsy Proven) - HIV positive, ineligible because of the increased risk of lethal infections when treated with marrow suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated - Pregnant or breastfeeding women are excluded from this study because the immunomodulatory treatment, preparative regimen, and anti-GVHD therapy contain agents with the potential for teratogenic or abortifacient effects. - Evidence of uncontrolled bacterial, viral, or fungal infections (currently taking medication and progression of clinical symptoms) within 1 month prior to starting the conditioning regimen. Patients with fever or suspected minor infection should await resolution of symptoms before starting the conditioning regimen. - Prior allogeneic marrow or stem cell transplantation. |
Country | Name | City | State |
---|---|---|---|
United States | University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center | Cleveland | Ohio |
Lead Sponsor | Collaborator |
---|---|
Case Comprehensive Cancer Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Probability of Engraftment | The number of patients with engraftment (as defined as recovery of ANC to 500 cells per cubic mm) compared to the total number of patients treated as a function of the patient's age. | 42 Days after transplant | |
Secondary | Mean time to engraftment | The average time to for engraftment (as defined as recovery of ANC to 500 cells per cubic mm) to occur estimated using a Kaplan-Meier curve as a function of the patient's age. | 42 Days after transplant | |
Secondary | Disease Progression | The average time (in days) to disease progression estimated using a Kaplan-Meier curve | 1 year | |
Secondary | Overall Survival | The average time (in days) patients are alive after treatment estimated using a Kaplan-Meier curve | 1 year | |
Secondary | Follicular Stimulating Hormone Levels | Estimated difference in changes in Follicular Stimulating Hormone Levels after transplant, among patients with matched sibling donors compared to patients with alternate donors. | 1 year | |
Secondary | Luteinizing Hormone Levels | Estimated difference in changes in Luteinizing hormone Levels after transplant, among patients with matched sibling donors compared to patients with alternate donors. | 1 year | |
Secondary | Testosterone Levels | Estimated difference in changes in Testosterone Levels after transplant, among male patients with matched sibling donors compared to patients with alternate donors. | 1 year | |
Secondary | Graft versus Host Disease | The number patients with Grade III-IVGraft versus Host Disease as defined by CTCAE v4.0 in matched sibling compared to alternate-donor graft recipients | 1 year | |
Secondary | Cerebral Vasculopathy | Vasculopathy may clinically manifest as a history of stroke. The difference in number of strokes before and after transplantation will be evaluated with paired statistical tests (t-test or McNemar). | 1 year | |
Secondary | Renal Vasculopathy | Vasculopathy may clinically manifest as macroalbuminuria (=300mg/g urinary albumin-to-creatinine ratio) or as a depressed estimated glomerular flow rate (eGFR). Evidence of renal vasculopathy before and after transplantation will be evaluated with paired statistical tests (t-test or McNemar). | 1 year | |
Secondary | Pulmonary Vasculopathy | Vasculopathy may clinically manifest as pulmonary arterial systolic pressure (PASP) by echo. Difference in PASP levels before and after transplantation will be evaluated with paired statistical tests (t-test or McNemar). | 1 year | |
Secondary | Hematopoiesis | Levels of stress hematopoiesis will be assessed by measuring telomere lengths with PCR before and after transplantation. These levels will be evaluated with paired statistical tests (t-test or McNemar). | 1 year | |
Secondary | Erythropoiesis | Levels of stress erythropoiesis will be assessed by measuring telomere lengths with PCR before and after transplantation. These levels will be evaluated with paired statistical tests (t-test or McNemar). | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02227472 -
Working Memory and School Readiness in Preschool-Aged Children With Sickle Cell Disease
|
||
Recruiting |
NCT06301893 -
Uganda Sickle Surveillance Study (US-3)
|
||
Recruiting |
NCT04398628 -
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
|
||
Completed |
NCT02522104 -
Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH)
|
Phase 4 | |
Recruiting |
NCT04688411 -
An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease
|
N/A | |
Terminated |
NCT03615924 -
Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease
|
Phase 3 | |
Not yet recruiting |
NCT06300723 -
Clinical Study of BRL-101 in Severe SCD
|
N/A | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Completed |
NCT04917783 -
Health Literacy - Neurocognitive Screening in Pediatric SCD
|
N/A | |
Completed |
NCT04134299 -
To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease
|
N/A | |
Completed |
NCT02580565 -
Prevalence of Problematic Use of Equimolar Mixture of Oxygen and Nitrous Oxide and Analgesics in the Sickle-cell Disease
|
||
Recruiting |
NCT04754711 -
Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition
|
N/A | |
Completed |
NCT04388241 -
Preliminary Feasibility and Efficacy of Behavioral Intervention to Reduce Pain-Related Disability in Pediatric SCD
|
N/A | |
Recruiting |
NCT05431088 -
A Phase 2/3 Study in Adult and Pediatric Participants With SCD
|
Phase 2/Phase 3 | |
Completed |
NCT01158794 -
Genes Influencing Iron Overload State
|
||
Recruiting |
NCT03027258 -
Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome
|
N/A | |
Withdrawn |
NCT02960503 -
Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02567695 -
A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects
|
Phase 1 | |
Completed |
NCT02565082 -
Evaluation of the Hemostatic Potential in Sickle Cell Disease Patients
|
N/A | |
Not yet recruiting |
NCT02525107 -
Prevention of Vaso-occlusive Painful Crisis by Using Omega-3 Fatty Acid Supplements
|
Phase 3 |